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Abbreviation   Definition 
 
aOR    adjusted odds ratio 
CI    confidence intervals 
CP    cerebral palsy 
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NHS    National Health Service (UK) 
NICU    neonatal intensive care unit 
NSTS    National Strategic Tracing Service (UK) 
NSW    New South Wales 
OCS    ORACLE Children Study 
ONS    UK Office of National Statistics 
OR    odds ratio 
PPROM    preterm prelabour rupture of membranes 
SPL    spontaneous preterm labour 
TPL    threatened preterm labour 
WHO    World Health Organisation 
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SUMMARY  
 
Cerebral palsy (CP) is the most common developmental disorder associated with lifelong 
motor impairment and disability. Although severe intrapartum hypoxia/ischaemia during 
birth may be instrumental in the causal pathway leading to cerebral palsy this accounts for 
only 10% of cases. Antenatal exposures that lead to cerebral palsy are, therefore, important to 
understand, particularly those that are modifiable. This application seeks to determine 
whether antenatal exposure to medications to prevent uterine contractions (tocolysis) and 
assist lung maturation (corticosteroids) have any association with cerebral palsy, particularly 
in pregnancies presenting moderately preterm. We plan to perform a secondary analysis on 
two large existing datasets (the ORACLE trials) of pregnancies presenting before term. If an 
association is found the results could have significant implications for clinical management 
and the direction of future research.  
 
OUTCOMES AND SIGNIFICANCE 
 
This international collaboration represents a unique opportunity to determine whether 
tocolysis and steroids are associated with the development of cerebral palsy in a broad range 
of preterm pregnancies. Given anecdotal reports of a trend towards the growing use of 
tocolysis and steroid cover in moderately and late preterm pregnancies,
1
 findings from this 
study could lead to significant practice change. 
 
BACKGROUND 
 
Cerebral palsy is a group of disorders that can involve brain and nervous system functions 
such as movement, learning, hearing, seeing, and thinking. It arises following injury or insult 
to the brain either in utero or in the early childhood period. It is the most common cause of 
motor disability in childhood, with a prevalence of 1.5–3 cases per 1000 births.2 There has 
been some previous research on the potential association of antenatal medications with 
subsequent CP.
3
 However, almost all of the children in those studies were exposed to 
treatment before 32 weeks gestation, when tocolysis and steroid cover is deemed a necessity. 
In contrast, for the ORACLE I and II trials, almost half the infants were enrolled after 32 
weeks gestation and about 30% were ultimately delivered at term.
4,5
 Optionality of 
tocolysis/steroids treatment could have existed for some of these infants. This study will 
examine whether fetal exposure to tocolysis and/or steroids is associated with cerebral palsy 
in moderately as well as very preterm infants. The exposure of interest is the intention to treat 
with tocolysis or steroids at the time of an ORACLE participant’s entry into the trial. The 
clinical decision explored is whether to administer tocolysis and steroids when imminent 
delivery is not certain. 
 
Previous analyses of the ORACLE trials found an association between antibiotic exposure 
and cerebral palsy among the ORACLE II infants. These trials were large pragmatic trials 
and in total recruited over 10 000 mothers.  The original ORACLE studies were designed to 
assess whether the administration of antibiotics to women at risk of early delivery either 
following preterm premature rupture of the membranes (PPROM) (ORACLE I)
5
 or 
threatened spontaneous preterm labour (SPL) (ORACLE II)
4
  improved neonatal outcomes.   
 
In Oracle 1
5
 
4826 women with PPROM were randomly assigned 250 mg erythromycin (n=1197), 325 mg 
co-amoxiclav (250 mg amoxicillin plus 125 mg clavulanic acid; n=1212), both (n=1192), or 
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placebo (n=1225) four times daily for 10 days or until delivery. The primary outcome 
measure was a composite of neonatal death, chronic lung disease, or major cerebral 
abnormality on ultrasonography before discharge from hospital 
 
In Oracle 2
4
 
6295 women with suspected or definite preterm labour with intact fetal membranes in whom 
there was substantial uncertainty as to whether antibiotics should be prescribed (ie 
spontaneous preterm labour with intact membranes and without evidence of clinical 
infection) were randomly assigned 250 mg erythromycin (n=1611), 325 mg co-amoxiclav 
(250 mg amoxicillin and 125 mg clavulanic acid; n=1550), both (n=1565), or placebo 
(n=1569) four times daily for 10 days or until delivery, whichever occurred earlier. The 
primary outcome measure was a composite of neonatal death, chronic lung disease, or major 
cerebral abnormality on ultrasonography before discharge from hospital 
 
The findings of these studies were that erythromycin given for up to 10 days to women with 
PROM led to a modest but statistically significant reduction in adverse short-term neonatal 
outcomes in singletons. In contrast, in ORACLE II, the administration of antibiotics to 
women in spontaneous preterm labour produced no benefit. In ORACLE II, the difficulty of 
diagnosing preterm labour accurately was also shown by the fact that 63·5% of women 
delivered after 37 weeks' gestation, despite being recruited much earlier in pregnancy.  
 
Having established short term indications for antibiotic use in women presenting at risk of 
preterm birth, a second set of studies (the ORACLE Children Studies [OCS]) were conducted 
to ascertain the long term outcomes of the babies in these studies.
6,7
  These studies began in 
2002 and sought follow-up information for surviving infants at 7 years of age from women 
who were recruited to the ORACLE trials in the UK including: 4378 infants who were born 
to 4148 women with PPROM who completed ORACLE I and 4473 infants who were born to 
4221 women with threatened preterm labour in ORACLE II.
6,7
 In the original trials, women 
were informed of the intention to do a subsequent follow-up assessment when they gave 
written informed consent. Children were traced with the help of the UK Office of National 
Statistics (ONS) and by contact with their family doctors (general practitioners; GPs). Details 
of deaths and families who moved out of the UK were notified by ONS. The families of 
children who had been adopted, were in foster care, or had emigrated were not contacted. 
 
Contact details of surviving children were obtained from the National Health Service (NHS) 
National Strategic Tracing Service (NSTS). If no response was obtained to an invitation 
letter, the child's GP was contacted to check details and possible reasons for non-response 
(eg, the child was currently in care or was a non-English speaker). Translations of all study 
materials were available. For those children who were not 7 years of age at the initial 
invitation, contact was maintained from 2001 onwards with birthday cards, newsletters, and 
change of address cards, and via a website. When the child was 7 years old their current 
address was confirmed with ONS and the GP. An information leaflet was sent to the parents, 
and 2 weeks later the study questionnaire was sent. If no response was obtained, contact 
details were checked with the GP and a reminder letter was sent by registered post to the 
parents or carers of the child during the week of the child's 7th birthday. If no response was 
forthcoming, 3 weeks later, a final letter was sent or telephone contact was made. 
 
The primary outcome of the OCS was defined as the presence of any level of functional 
impairment (severe, moderate, or mild) derived from the mark III MAHS classification 
system
8
 within any of the individual attributes of vision, hearing, speech, ambulation, 
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dexterity, emotion, cognition, or pain. Each attribute has either five or six defined levels of 
impairment, ranging from normal function to severe dysfunction. These have been classified 
further into none, mild, moderate, or severe levels of severity for the individual attributes 
from the standard algorithms available within the HUI coding/procedure manual. The overall 
level of functional impairment was determined by their worst score on any attribute.  
 
For children whose mothers had PPROM, the prescription of antibiotics seemed to have little 
effect on the health and educational attainment of children at 7 years.
7
 This was unexpected. 
It would have been assumed that the early benefit would improve longer term clinical 
outcomes for these children. 
 
For children whose mothers had spontaneous preterm labour the prescription of erythromycin 
(with or without co-amoxiclav) was associated with an increase in the proportions of children 
with any level of functional impairment from 38% to 42% (OR 1.18, 95% CI 1.02–1.37)6. 
Similarly proportions of children with cerebral palsy increased from 1.7% to 3.3% (OR 1.93, 
95% CI 1.21–3.09) associated with erythromycin and from 1.9% to 3.2% (OR 1.69, 95% CI 
1.07–2.67) with co–amoxiclav. There was a suggestion that more children who developed 
cerebral palsy had been born to mothers who had received both antibiotics. 
 
Comparing the long term outcomes between the two ORACLE studies is intriguing.
6,7
 Whilst 
not being a randomised comparison the following observations are particularly pertinent 
which are abstracted from the original Lancet publications: 
 
1. The incidence of cerebral palsy is highest in the babies that were born having been 
exposed to antibiotics with intact membranes 
2. This incidence of cerebral palsy is higher following exposure to antibiotics with intact 
membranes than for those babies who received antibiotics with ruptured membranes  
3. This high incidence of cerebral palsy is despite the fact that as a group those babies 
who received antibiotics with intact membranes were born: 
a. 3-4 weeks later 
b. weighed 800g more 
c. were half as likely to have been ventilated 
d. were half as likely to have been admitted to NICU 
e. were less likely to have had a positive blood culture, NEC  or an abnormal 
head ultrasound. 
 
 
One exposure that is markedly different between the two groups and that has not, to date, 
been investigated as an independent risk factor is tocolysis. Tocolysis usage was 4-5 times 
higher in the women who presented with threatened preterm labour (~61%) compared with 
ruptured membranes (~12%).
4,5
 Steroid use was also somewhat higher in women with 
threatened preterm labour (81% versus 77%).
4,5
 The extract from the trial entry form below 
details the information about tocolysis and steroids that was collected for each participant: 
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With strategies for preventing preterm birth largely unsuccessful, women presenting with 
signs and symptoms of threatened preterm labour remain a frequent clinical challenge. In 
these situations, tocolytic drugs are widely used in an attempt to delay or even prevent 
preterm birth.
9
 The primary objective of tocolytic therapy is to prolong pregnancy sufficiently 
to provide time for the administration of antenatal steroids to improve fetal lung maturity and 
maternal transport to a hospital with a NICU. Almost all infants exposed to tocolytic therapy 
will also be exposed to steroid therapy, although only a fraction of women who receive 
steroids are managed with tocolytics. The use of tocolytics is controversial, as there is no 
evidence to show that tocolysis improves perinatal outcomes, a conclusion that has recently 
been underlined by WHO.
10
 This uncertainty is reflected in divergent global practice.
11,12
 
Some countries use minimal or no tocolysis. Use of tocolysis and steroids by centre in 
ORACLE was unreported but probably varied considerably. Furthermore, there is a wide 
range of agents used in those centres that do administer tocolysis.  One of the earliest 
tocolytics utilized for this purpose was ethanol infusion, although this is not generally used in 
current practice due to safety concerns for both the mother and her baby. Other agents studied 
to date include magesium sulphate, β agonists (β sympathomimetic agents: ritrodrine, 
salbutamol, terbutaline), prostaglandin synthesis inhibitors (indomethacin, ibuprofen, 
sulindac), calcium channel blockers (nifedipine), oxytocin antagonists (atosiban), and nitric 
oxide donors (glyceryl trinitrate). Although there are 11 Cochrane Reviews of the short-term 
effects of tocolysis,
13-23
 there are few studies with long-term outcomes. An exception is 
EPICURE, a follow-up study of extremely preterm infants (20-25 weeks) born in UK and 
Ireland in 1995. EPICURE reported an independent association between tocolysis and both 
seriously abnormal scan findings (OR 2.02, 95%CI 1.04-3.94) and long term oxygen 
dependency (OR 2.53, 95%CI 1.42-4.51).
24
  
 
Complex interactions of a potentially hostile uterine environment and obstetric management 
(including antibiotics, tocolysis, corticosteroids) may expose the fetus to pathophysiological 
changes that lead to or prevent cerebral injury. Women who present at risk of early birth who 
are administered tocolytics and steroids and/or antibiotics may have a prolonged exposure to 
a potentially injurious environment but the fetus can also benefit from additional days of 
gestation and maturation. Less certain is whether there could be neurodevelopmental 
consequences of exposure to tocolysis or steroids. Animal studies have reported mixed 
results, with the possibility of protective effects or impairment.
25,26
 One study in humans that 
followed up antenatal corticosteroid exposure reported a higher rate of CP at 2 to 3 years of 
age among infants exposed to repeat courses of antenatal steroids compared to a single course 
(2.9% versus 0.5%) but this was not statistically significant as this was based on only 7 cases 
of CP.
27
  A similar study among earlier gestations and with higher rates of CP found no 
difference in the risk of CP for repeat versus single course of steroids.
28
 
 
We will use the rich data set within the ORACLE studies
4-7
 to explore hypotheses related to 
antenatal exposures and cerebral palsy. Importantly, the study includes pregnancies 
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presenting at moderate and late preterm gestations and will be generalisable to a broader 
population of pregnancies than previous studies. The aim is to assess whether exposure to 
tocolytics and/or steroids while the fetus is still developing increases or decreases the risk of 
cerebral palsy or death as the primary outcome. This composite outcome is necessary as 
cerebral palsy and deaths are competing outcomes. The secondary outcome will be any 
diagnosis of cerebral palsy. Our null hypothesis is that intention to treat with tocolytics or 
steroids is not associated with cerebral palsy or childhood death. Alternative hypotheses are 
that treatment may either increase or decrease the risk of CP. 
 
 
RSEARCH PLAN 
 
We will utilise data from the ORACLE I and ORACLE II randomised trials and the follow-
up ORACLE Children Studies (OCS) I and II to examine any association between tocolysis 
and/or steroids, and death or cerebral palsy by 7 years of age.
4-7
 The ORACLE studies 
evaluated the impact of antibiotics on pregnancy and childhood outcomes for women at risk 
of early birth due to preterm prelabour rupture of the membranes (ORACLE I) or suspected 
or definite preterm labour with intact fetal membranes (ORACLE II). The eligibility criteria 
were the same for both trials except with respect to the presenting condition (PPROM or 
spontaneous preterm labour [SPL]). In both trials antibiotics were randomized in a factorial 
design (erythromycin or co-amoxiclav or both or placebo). Between 1994 and 2000, women 
were recruited from 161 participating centres in 14 countries, For ORACLE I, 92.2% of 
participants were recruited in the UK and for ORACLE II 69.9% were UK recruits.
6,7
 
 
Childhood follow-up was only attempted for UK-recruited participants. Because the OCS 
assessed childhood outcomes, only infants discharged alive from the ORACLE trials were 
included. Based on OCS publications, childhood deaths in the UK are fully enumerated but 
information on CP is only available for the 75% of children with returned questionnaires or 
GP/parent contact from ORACLE I and 71% from ORACLE II.
6,7
 
 
Eligibility Criteria 
Children who survived the neonatal period (first 28 days of life) born to women recruited in 
the UK and who had any definite follow-up, including either a questionnaire response or 
other parent contact, or notification of death subsequent to the neonatal period.  
We have chosen to include ORACLE infants who were alive at the end of the neonatal period 
as this is a widely accepted threshold separating the perinatal period from longer term infant 
and child outcomes.
27,28
  
 
A flow diagram illustrating the formation of the study population will be included in the 
Results. A draft version of the flow diagram is attached as Figure 1. 
 
Outcomes 
Primary Outcome:  
A composite of death or CP by 7 years of age. This combined variable is necessary because 
cerebral palsy and death are competing outcomes, some deaths could have been undiagnosed 
cases of CP.
27,28
 
 
Details of the OCS study methods have been published previously,
6,7
 and reported in the 
Background section of this study plan. Briefly, cases of CP were usually identified from 
returned OCS questionnaires. The questionnaires were sent out to families when the child 
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reached seven years of age. In a further follow-up study of the OCS children reported to have 
CP (n=93, 56% of the children  with CP in OCS), all parental reported cases were confirmed 
by a physiotherapist.
29
 A few additional cases were identified by GP or parent contact or by 
death notification. Notifications of death include descriptions of the contributing causes, 
which could include cerebral palsy.  
 
Secondary outcome 
Any report of CP. 
 
Exposures 
Tocolysis 
Information on already prescribed or definitely intended exposure to tocolysis and steroids 
was collected at trial entry. Type of tocolytic is important because the mechanisms of action 
and the potential adverse reactions differ. Specific fields in the form were provided for beta-
agonists, indomethacin, and nifedipine, and an “other” drugs text field was also used. The 
“other” field recorded use of glyceryl trinitrate [GTN] patches and magnesium sulphate, and 
also some use of drugs which properly belonged in one of the specified class fields (i.e. 
ritodrine and intravenous salbutamol could have been ticked as beta agonists). Magnesium 
sulphate could have been considered as a tocolytic agent at the time of the ORACLE trials 
but no UK centre reported its use. No use of atosiban was recorded at any trial centre.  
 
Although some women would have been exposed to more than one tocolytic agent, tocolysis 
will be categorized into mutually exclusive categories: 1) any use of beta agonist with or 
without other tocolysis  2) nifedipine alone  3) indomethacin alone  4) a small “other” 
category including any GTN patch use or any nifedipine/indomethacin combination. The beta 
agonists were the most commonly used tocolytic in the UK at the time of the ORACLE trials 
but are now less used due to their higher rate of adverse reactions.
11
  Nifedipine and 
indomethacin are still in use and it is desirable that any comparison be untainted by co-
administration of a beta agonist or other tocolytics. 
 
Steroids 
Only available as a tick box for completed/intended treatment with steroids. There was no 
differentiation between betamethasone and dexamethasone, nor any indication whether a full 
course was completed. 
 
Covariates for models 
Factors which may be associated with CP and that exist at presentation/randomization and are 
available in the data sets include gestational age at trial entry, presentation (PPROM or SPL), 
maternal age, multiple pregnancy, cervical dilatation and sex of infant.
30,31
 Maternal age will 
be categorised as: <20, 20-34, ≥35 years. Cervical dilatation will be categorised as > 1 cm 
(yes or no). Where no dilatation is recorded, this will be categorised as “no”. In addition, 
ORACLE II found an association between antibiotic administration and CP among women 
with SPL. Therefore there will be separate indicators for assigned treatment with 
erythromycin and for assigned treatment with co-amoxiclav. 
 
Gestational age at birth will not be a covariate in any model. The purpose of tocolysis is to 
prolong gestational age, gestation at birth is directly on the causal pathway to the outcomes. 
Thus, gestational age is a potential intermediate, not a confounder of an association between 
tocolysis/steroids and cerebral palsy.
32-35
 Gestational age at birth was unknown at the time of 
trial entry and is unknown at the time of any clinical decision about whether to administer 
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tocolysis and steroids. Only gestational age at trial entry, as noted in the preceding paragraph, 
will be used for gestational age adjustment.  Maternal, socio-economic or pregnancy 
indicators other than those mentioned here were not recorded in the ORACLE I and II trial 
entry databases so cannot be assessed for potential confounding. 
 
Sample size 
Sample size is predefined by the number of children discharged from each ORACLE trial and 
with some follow-up (n>3,000 for each trial). We estimate that there will be 80% power to 
detect a CP risk of OR=1.9 or OR=0.5 associated with beta agonists, and 80% power to 
detect an OR=1.8 or OR=0.3 of CP risk associated with steroid treatment in the ORACLE II 
cohort.   
 
Statistical analysis 
We will compare the trial entry characteristics on key variables (eg PPROM or SPL, 
tocolysis, steroids, multiple pregnancy, infant sex and gestational age at birth) for infants with 
and without childhood follow-up information among those recruited at UK centres, and test 
for and report any statistically significant differences. 
 
We will describe tocolytic use by type of medication, including use of multiple tocolytics. 
The distribution of tocolysis and steroid treatment and of covariate risk factors will be 
reported by ORACLE presentation (PPROM or SPL). No statistical testing of the 
characteristics of the two baseline groups is contemplated as they are known to be different 
study populations a priori. A draft Table 1 is attached which shows what we plan to report.  
 
The ORACLE I and II cohorts of eligible children will initially be analysed and reported 
separately. However, the pregnancy eligibility criteria were the same except for presenting 
condition. If the adjusted effect estimates for ORACLE I and II show no evidence of 
heterogeneity, we will combine the trial datasets into one model with presenting condition as 
an added covariate, and report results for the combined data 
 
The associations between tocolysis and steroids and the study outcomes will be examined by 
fitting multilevel regression models of the dichotomous primary and secondary outcomes. 
Recruiting centre will be the second level (hierarchical) factor in the multilevel analysis, to 
take account of the similarities of maternal characteristics (such as demographic and health 
behaviour attributes) and obstetric management practices at each trial centre (cluster effect). 
The SAS procedure GLIMMIX with random intercepts will be used for the multilevel 
analyses. Separate models will be performed for the ORACLE I and ORACLE II cohorts. 
The model betas and standard errors for the outcome effect estimates associated with 
tocolysis (and steroid) exposures for the two cohorts will be compared using a chi squared 
test for homogeneity of effect. If the homogeneity P value for any comparison of effects 
indicates a probability that both cohorts are likely to have the same population mean effect (a 
P value >0.50) then the ORACLE I & II cohorts will additionally be combined for that 
outcome. The regression model for the combined cohorts will then have an indicator for 
presentation (PPROM or SPL) included as a covariate.  Combining the cohorts if P>0.50 is 
more conservative than combining the cohorts if the test for homogeneity does not fall below 
the usual P<0.05 criterion; it ensures that the combination of cohorts will only occur if there 
is at least a 50% chance that the true population risks are the same for each cohort. A draft 
Table 2 is attached which shows what we plan to report. 
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The effect estimates of the models will be adjusted odds ratios and 95% confidence intervals 
(95% CI). The odds ratio provides a good estimate of the RR when the outcome is not 
common (primary outcome is expected to be <5%).  
 
We will perform subgroup analyses of the primary and secondary outcomes by gestational 
age at trial entry, categorised as either <32 weeks gestation or ≥32 weeks gestation (roughly 
half of ORACLE pregnancies were recruited at ≥32 weeks). These results may be 
summarised in the text or may be reported in tables similar to Table 2. A sensitivity analysis 
will be performed by including only sigletons and the first infant from any multiple 
gestations. 
  
No mediation analysis involving gestational age at birth is planned since such an analysis 
would not provide clinically useful information. The clinical question is whether to 
administer tocolysis and steroids to women presenting with PPROM or threatened preterm 
labour; there is no certainty at the time of presentation what the actual gestational age at birth 
will be. Making a distinction between the effect of prolongation of gestational age, normally 
only 48 hours if tocolysis is effective, and the other effects of tocolysis/steroids would be 
irrelevant to decision making at the time of presentation.  Furthermore, causal mediation 
analysis assumes no unmeasured confounding (common causes) in the exposure-outcome, 
mediator-outcome and exposure-mediator relations, and these assumptions cannot be met.
32-35
 
 
 
 
DATA MANAGEMENT 
 
Data collection and consent 
All data collected for the ORACLE I, ORACLE II and OCS studies were fully consented to 
by the trial participants. For the original ORACLE trials, participants were informed of the 
intention to do a subsequent follow-up assessment when they gave written informed consent. 
For the follow-up OCS trials, consent for collection of specific follow-up outcomes was 
sought from the women who could be contacted. The OCS studies were approved by the 
West Midlands Multi-centre Research and Ethics Committee. Our planned analyses will only 
use data previously collected by the ORACLE and OCS trials including the outcome of 
cerebral palsy, which has been reported on in the OCS published study results.
6,7,29
 The 
distribution of antenatal tocolytics and steroids has been reported on in the ORACLE 
publications.
4,5
 No further contact with participants is necessary. The ORACLE I, ORACLE 
II and OCS databases have been reviewed by the UK data custodian (the Birmingham 
Clinical Trials Unit; contact is Sara Kenyon) and a Material Transfer Agreement with our 
research group has been approved. Use of these data for research will require local ethics 
committee approval as the study question (the exposure of interest) differs from the OCS 
exposure of interest (antenatal antibiotics). Tocolysis and steroids use were reported as 
baseline characteristics for the original trials but no association with trial outcomes was 
analysed. The data files necessary for the proposed analyses have been transferred via secure 
file transfer protocol (FTP) to the site of the planned analysis at the Clinical and Population 
Perinatal Health Research group at the Kolling Institute. The data were transferred as 
encrypted password-protected files. 
 
Asking women for additional consent to specifically perform the proposed analyses is not 
feasible due to the large number of participants and the time since the original trials (recruited 
1994-2000). Furthermore, this would require that the researchers access personal information 
Page 11 of 16 
 
that is not available in the deidentified datasets. In addition, a high proportion of women are 
likely to have moved and the resulting non−response bias would compromise the validity and 
generalisability of the results. Finally there is a risk of raising anxiety or other harms among 
women who experienced a subsequent adverse event or whose child has had an adverse 
event. 
 
Data storage 
All data files are in electronic, de-identified format and stored on a secure server in the 
Kolling Building at the Northern Sydney Local Health District on a password-protected local 
area network with access limited to the research personnel. The server cannot be accessed 
remotely. Accredited professional IT staff manage the server implementing standard security 
and access measures to prevent the loss, misuse, theft and unauthorised access of data. 
 
Data sharing policy 
Any sharing of data will require the consent of the UK data custodian for the ORACLE trials. 
Researchers with a potential project can contact Sara Kenyon (s.kenyon@bham.ac.uk). A 
study plan or protocol for a proposed analysis, which will need to contain clear scientific 
justification for the particular project, anticipated outputs and timelines will be required.  
Independent peer review of a project may be required. Approval from an institutional ethics 
committee for the study will also be required. Funds are required to support the data extract 
and transfer.  
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Table 1  Pregnancy characteristics for ORACLE 1 and ORACLE II children with post neonatal 
follow up. 
   
At trial entry ORACLE I (PPROM) ORACLE II (SPL) 
   
Maternal age (years)   
    <20 years   
    20-34 years   
    ≥35 years   
Gestational age (weeks)   
Multiple gestation   
Cervix dilatation > 1 cm   
Tocolysis   
    Beta agonist   
    Nifedipine alone   
    Indomethacin alone   
    Other*   
    None   
Corticosteroids   
Assigned to erythromycin   
Assigned to co-amoxiclav   
Infant sex   
*  GTN patch or any combination of nifedipine, indomethacin or GTN patch 
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Table 2  Adjusted risks of primary and secondary outcomes associated with exposure to 
intended treatment with tocolytics and steroids at trial entry. 
 CP or death 
ORACLE I 
aOR (95% CI) 
CP or death 
ORACLE II 
aOR (95% CI) 
test of 
aOR’s 
(P value) 
CP or death 
ORACLE I & II 
aOR (95% CI)  
Tocolysis     
  Beta agonist     
  Nifedipine     
  Indomethacin     
  Other     
  None (referent)     
     
Corticosteroids     
     
 CP 
ORACLE I 
aOR (95% CI) 
CP 
ORACLE II 
aOR (95% CI) 
test of 
aOR’s 
(P value) 
CP 
ORACLE I & II 
aOR (95% CI) 
Tocolysis     
  Beta agonist     
  Nifedipine     
  Indomethacin     
  Other     
  None (referent)     
     
Corticosteroids     
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Figure 1  Flow diagram of the formation of the study population for analysis. 
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